Intensive Care Medicine

, 37:1432 | Cite as

Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality

  • Christian Torgersen
  • Günter Luckner
  • Daniel C. H. Schröder
  • Christian A. Schmittinger
  • Christopher Rex
  • Hanno Ulmer
  • Martin W. Dünser



To evaluate the association between concomitant arginine-vasopressin (AVP)/hydrocortisone therapy and mortality in severe septic shock patients.


This retrospective study included severe septic shock patients treated with supplementary AVP. To test the association between concomitant AVP/hydrocortisone use and mortality, a multivariate regression and Cox model (adjusted for admission year, initial AVP dosage and the Sepsis-related Organ Failure Assessment score before AVP) as well as a propensity score-based analysis were used. In both models, intensive care unit (ICU) and 28-day mortality served as outcome variables.


One hundred fifty-nine patients were included. Hydrocortisone was administered to 76 (47.8%) at a median daily dosage of 300 (200–300) mg. In the multivariate logistic regression model, concomitant use of AVP and hydrocortisone was associated with a trend towards lower ICU (OR, 0.51; CI 95%, 0.24–1.08; p = 0.08) and 28-day (HR, 0.69; CI 95%, 0.43–1.08; p = 0.11) mortality. The probability of survival at day 28, as predicted by the regression model, was significantly higher in patients treated with concomitant AVP and hydrocortisone compared to those receiving AVP without hydrocortisone (p = 0.001). In a propensity score-based analysis, ICU (45 vs. 65%; OR, 0.69; CI 95% 0.38–1.26; p = 0.23) and 28-day mortality (35.5 vs. 55%; OR, 0.59; CI 95%, 0.27–1.29; p = 0.18) was not different between patients treated with (n = 40) or without concomitant hydrocortisone (n = 40).


Concomitant AVP and hydrocortisone therapy may be associated with a survival benefit in septic shock. An adequately powered, randomised controlled trial appears warranted to confirm these preliminary, hypothesis-generating results.


Arginine–vasopressin Hydrocortisone Septic shock Mortality 

Supplementary material

134_2011_2312_MOESM1_ESM.ppt (108 kb)
Supplementary material 1 (PPT 108 kb)


  1. 1.
    Luckner G, Dünser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B (2005) Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33:2659–2666PubMedCrossRefGoogle Scholar
  2. 2.
    Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, Holmes CL, Hébert PC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ (2010) The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36:83–91PubMedCrossRefGoogle Scholar
  3. 3.
    Dünser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107:2313–2319PubMedCrossRefGoogle Scholar
  4. 4.
    Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, VASST Investigators (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887PubMedCrossRefGoogle Scholar
  5. 5.
    Russell JA, Walley KR, Gordon AC, Cooper J, Hebert PC, Singer J, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, for the VASST investigators (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37:811–818PubMedCrossRefGoogle Scholar
  6. 6.
    Bauer SR, Lam SW, Ch SS, Oyen LJ (2008) Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: a case control study. J Crit Care 23:500–506PubMedCrossRefGoogle Scholar
  7. 7.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874CrossRefGoogle Scholar
  8. 8.
    Luckner G, Mayr VD, Jochberger S, Wenzel V, Ulmer H, Hasibeder WR, Dünser MW (2007) Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 35:2280–2285PubMedCrossRefGoogle Scholar
  9. 9.
    Torgersen C, Dünser MW, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, Lorenz I, Schmid S, Westphal M, Grander W, Luckner G (2010) Comparing two different vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 36:57–65PubMedCrossRefGoogle Scholar
  10. 10.
    Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30:536–555PubMedCrossRefGoogle Scholar
  11. 11.
    Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60PubMedCrossRefGoogle Scholar
  12. 12.
    Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963PubMedCrossRefGoogle Scholar
  13. 13.
    Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG, on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:707–710PubMedCrossRefGoogle Scholar
  14. 14.
    Gayat E, Pirracchio R, Resche-Rigon M, Mebazza A, Mary JY, Porcher R (2010) Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med 36:1993–2003PubMedCrossRefGoogle Scholar
  15. 15.
    Annane D, Sébille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedCrossRefGoogle Scholar
  16. 16.
    Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J, CORTICUS Study Group (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124PubMedCrossRefGoogle Scholar
  17. 17.
    Batalhao ME, Moreto V, Stabile AM, Antunes-Rodrigues J, Carnio EC (2008) Role of dexamethasone on vasopressin release during endotoxemic shock. Regul Pept 147:67–71PubMedCrossRefGoogle Scholar
  18. 18.
    Bähr V, Franzen N, Oelkers W, Pfeiffer AF, Diederich S (2006) Effect of exogenous glucocorticoid on osmotically stimulated antidiuretic hormone secretion and on water reabsorption. Eur J Endocrinol 155:845–848PubMedCrossRefGoogle Scholar
  19. 19.
    Gillies GE, Linton EA, Lowry PJ (1982) Corticotrophin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299:355–357PubMedCrossRefGoogle Scholar
  20. 20.
    Ertmer C, Bone HG, Morelli A, Van Aken H, Erren M, Lange M, Traber DL, Westphal M (2007) Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 27:281–288PubMedCrossRefGoogle Scholar

Copyright information

© Copyright jointly held by Springer and ESICM 2011

Authors and Affiliations

  • Christian Torgersen
    • 1
  • Günter Luckner
    • 2
  • Daniel C. H. Schröder
    • 2
  • Christian A. Schmittinger
    • 1
  • Christopher Rex
    • 3
  • Hanno Ulmer
    • 4
  • Martin W. Dünser
    • 5
  1. 1.Department of Intensive Care MedicineInselspital, Bern Medical UniversityBernSwitzerland
  2. 2.Department of Anaesthesiology and Intensive Care MedicineInnsbruck Medical UniversityInnsbruckAustria
  3. 3.Department of Anaesthesiology and Intensive Care MedicineKreiskliniken ReutlingenReutlingenGermany
  4. 4.Department of Medical Statistics, Informatics and Health EconomicsInnsbruck Medical UniversityInnsbruckAustria
  5. 5.Department of Anaesthesiology and Intensive Care MedicineSalzburg General Hospital and Paracelsus Private Medical UniversitySalzburgAustria

Personalised recommendations